Balal Shafi, Than Jonathan, Tekriwal Sharmila, Lobo Aires
Moorfields Eye Hospital, Bedford, UK.
Ophthalmologica. 2018;239(1):36-44. doi: 10.1159/000479893. Epub 2017 Sep 27.
Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab.
We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up.
Patients (n = 129) had a mean follow-up of 19.9 months. The mean improvement in central retinal thickness was 312 μm after final DEX (p = <0.0001). Mean peak best corrected visual acuity (BCVA) after final DEX was an improvement of 16 ETDRS letters (p < 0.0001). Forty-nine patients were converted and received a mean of 9.37 ranibizumab injections with a mean improvement in BCVA of 15 ETDRS letters (p < 0.0001) compared with final DEX.
This study supports the use of ranibizumab in eyes previously treated with DEX and provides long-term efficacy and safety data for multiple DEX injection.
评估视网膜静脉阻塞（RVO）患者的治疗结果，包括：（1）多次重复注射地塞米松（DEX）以及（2）从DEX转换为雷珠单抗治疗的情况。
我们进行了一项回顾性研究，评估了在英国贝德福德的摩尔菲尔德眼科医院接受多次DEX注射以及需要转换为雷珠单抗治疗的患者的治疗结果。所有患者均接受了全面的眼科检查。
患者（n = 129）的平均随访时间为19.9个月。末次DEX注射后，视网膜中央厚度平均改善了312μm（p = <0.0001）。末次DEX注射后的平均最佳矫正视力（BCVA）峰值提高了16个ETDRS字母（p < 0.0001）。49例患者转换治疗，平均接受了9.37次雷珠单抗注射，与末次DEX注射相比，BCVA平均提高了15个ETDRS字母（p < 0.0001）。
本研究支持在先前接受DEX治疗的眼中使用雷珠单抗，并提供了多次DEX注射的长期疗效和安全性数据。
